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Introduction 
Since the landmark study of Omura et al.,1 prophylactic cra-
nial irradiation has become a useful adjunct to intrathecal
methotrexate for the prevention of central nervous system
(CNS) recurrence in adult patients with acute lymphoblastic
leukemia (ALL). Given that the risk of CNS relapse is less than
5% with modern ALL therapy, due to the concurrent use of
CNS-penetrating agents such as high-dose
methotrexate/cytarabine (HD-M/A),2-4 attempts to omit cra-
nial irradiation were initiated in an effort to minimize
chemotherapy delay and risks of direct or cumulative CNS
toxicity. The issue of irreversible neurotoxicity caused by
radiotherapy has become prominent in long-term survivors of
childhood ALL. A high incidence of secondary cancers,5 cog-
nitive dysfunction6,7 and organic brain damage detectable by
magnetic resonance imaging and favoring early onset demen-
tia8 have been described. Because the outcome of adolescents
and younger adults with ALL has greatly improved using
pediatric-type protocols,9-11 long-term radiation-related haz-
ards can become of great concern for many patients cured by
these programs. 
The cure rate of childhood ALL can be outstanding, and the
omission of cranial irradiation does not affect survival or risk
of CNS relapse.12 With total therapy program XV, Pui et al.
obtained a 85.6% 5-year event-free survival rate.13 In this
study CNS prophylaxis was radiation-free and consisted of
triple intrathecal therapy (ITT), which proved superior to
standard intrathecal methotrexate in a randomized clinical
trial,14 along with systemic CNS-active therapy. The risk of
CNS progression was low (3.9%) and comparable to that
observed in other pediatric trials, with or without cranial irra-
diation. Because in this study only the risk of marrow relapse
but not that of CNS relapse was decreased, further intensifi-
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Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic
leukemia, to avoid the long-term toxicity associated with cranial irradiation. In a  randomized, phase II trial
enrolling 145 adult patients, we compared intrathecal liposomal cytarabine (50 mg: 6/8 injections in B-/T-cell sub-
sets, respectively) with intrathecal triple therapy (methotrexate/cytarabine/prednisone: 12 injections). Systemic
therapy included methotrexate plus cytarabine or L-asparaginase courses, with methotrexate augmented to 2.5
and 5 g/m2 in Philadelphia-negative B- and T-cell disease, respectively. The primary study objective was the com-
parative assessment of the risk/benefit ratio, combining the analysis of feasibility, toxicity and efficacy. In the lipo-
somal cytarabine arm 17/71 patients (24%) developed grade 3-4 neurotoxicity compared to 2/74 (3%) in the triple
therapy arm (P=0.0002), the median number of  episodes of neurotoxicity of any grade was one per patient com-
pared to zero, respectively (P=0.0001), and even though no permanent disabilities or deaths were registered, four
patients (6%) discontinued intrathecal prophylaxis on account of these toxic side effects (P=0.06). Neurotoxicity
worsened with liposomal cytarabine every 14 days (T-cell disease), and was improved by the adjunct of intrathecal
dexamethasone. Two patients in the liposomal cytarabine arm suffered from a meningeal relapse (none with T-
cell disease, only one after high-dose chemotherapy) compared to four in the triple therapy arm (1 with T-cell dis-
ease). While intrathecal liposomal cytarabine could contribute to improved, radiation-free central nervous system
prophylaxis, the toxicity reported in this trial does not support its use at 50 mg and prompts the investigation of
a lower dosage. (clinicaltrials.gov identifier: NCT-00795756).
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ABSTRACT
cation of intrathecal prophylaxis was planned. 
Intrathecal liposome-encapsulated cytarabine
(DepoCyte®, ITD) might be advantageous in this setting,
the slow cytarabine release allowing therapeutic drug con-
centrations in the cerebrospinal fluid for up to 14 days.15,16
In adult ALL, ITD was highly effective at the time of CNS
recurrence. Goekbuget et al. obtained 12 complete remis-
sions with one or two ITD injections in 14 adult patients
with CNS relapse (86%);17 however, 21% of them devel-
oped severe neurotoxicity. In primary CNS prophylaxis,
three to six ITD injections were used together with the
HyperCVAD regimen, which included four HD-M/A
courses. Jabbour et al. at M.D. Anderson Cancer Center
(MDACC) reported prohibitive neurotoxicity in five out
of 31 of these patients (16%).18 However, the intervals
between HD-M/A and ITD were rather short (ITD on day
10 of HD-M/A) and no patient suffered from CNS relapse. 
The Northern Italy Leukemia Group (NILG) performed
a randomized phase II trial of radiation-free CNS prophy-
laxis comparing standard ITT (methotrexate, cytarabine,
corticosteroids) with ITD. The treatment included three
HD-M/A courses, with longer intervals between any ITD
and HD-M/A courses (21 days) and higher methotrexate
and lower cytarabine dosages than in the MDACC study
(methotrexate 1.5-5 g/m2 and cytarabine 2 g/m2 instead of
1 g/m2 and 3 g/m2, respectively). The primary study end-
point was to assess the risk/benefit ratio of this strategy, in
view of the safety issue raised by the MDACC study and
the paucity of comparative clinical data in primary CNS
prophylaxis of adult ALL. 
Methods 
Diagnosis and treatment
Diagnostic criteria and the treatment program with minimal
residual disease/risk-oriented hematopoietic stem cell transplanta-
tion (HSCT) are detailed in the Online Supplement. The study was
approved by the Institutional Review Boards of all participating
institutions. Eligible patients signed an informed consent form in
accordance with the Helsinki declaration of 1975, as revised in
2008. 
Central nervous system  prophylaxis trial
Pre-random stratification was by B- or T-cell cell lineage and risk
class [standard risk: white blood cell count <30x109/L, pre-B/”com-
mon” phenotype, BCR-ABL1-negative (B-ALL) or <100x109/L and
cortical-T CD1a+ phenotype (T-ALL)]. Patients were randomized
to ITT (methotrexate 12.5 mg, cytarabine 50 mg, prednisone 40
mg) or ITD 50 mg as shown in Figure 1. Although intrathecal pro-
phylaxis was discontinued at resistance, recurrence or HSCT, all
the patients were evaluable until they received the allocated
intrathecal prophylaxis. Other CNS-active therapy included line-
age-targeted methotrexate19,20 at 2.5 g/m2 in Philadelphia chromo-
some/BCR-ABL1-negative (Ph–) B-ALL and 5 g/m2 in T-ALL (age
≤55 years), together with high-dose cytarabine 2 g/m2 (8 doses, 2
courses) or L-asparaginase 10,000 IU/m2 (2 doses, 1 course). No
specific recommendation for intrathecal prophylaxis at/after
HSCT was made in this study.
Study design
The study was sponsored by “Papa Giovanni XXIII” Hospital
(Bergamo, Italy), on behalf of the NILG.  The primary endpoint
was the comparative evaluation of the risk/benefit profile of the
two CNS prophylaxis strategies. Because of the low number of
expected CNS recurrences and the planned number of study
patients (n=150) no formal sample size estimate was felt appropri-
ate. Instead, close monitoring and validation of occurring events
under the supervision of a Data Safety Monitoring Board was
planned to spot any suspected safety risk promptly. 
Neurotoxicity was evaluated according to the National Cancer
Institute Common Toxicity Criteria (http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)
and feasibility according to the number of total intrathecal injec-
tions administered versus planned number. The benefit was
assessed comparing rates of isolated and combined CNS recur-
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Figure 1. Study design. ITT
was administered on days
1 and 15 of courses 1, 2
and 8; on day 1 of courses
4, 6 and maintenance
months 2, 3, 4 and 5
(x12).  ITD was adminis-
tered on day 1 of courses
1, 2, 4, 5, 7, 8 and main-
tenance month 2 (x6, B-
ALL); plus day 15 of cours-
es 1 and 8 in T-ALL (x8).
Except for courses 1-2
and 8 in T-ALL, an interval
of 21 days was main-
tained between any ITD
and/or high-dose course.
Concomitant systemic
dexamethasone 5
mg/m2/bd was given for
5 days with each intrathe-
cal injection.
rence. The protocol was amended in December, 2010, when
intrathecal dexamethasone 4 mg was added to ITD in an attempt
to decrease the incidence of severe backache and headache (also
substituting for prednisone in the ITT arm).
Definitions and statistics
Standard definitions of complete remission, early death, resist-
ance, isolated or combined bone marrow relapse, overall survival
and disease-free survival were adopted.21,22 A CNS relapse was
defined by the morphological and immunophenotypic detection
of B- or T-lymphoblasts in the cerebrospinal fluid of patients who
had been in complete remission and who were developing signs
of neuromeningeal disease, with or without abnormal findings on
computed tomography or magnetic resonance imaging. Serial
immunophenotypic evaluation of cerebrospinal fluid from
patients in complete remission was not planned.
The patients’ baseline characteristics and number of intrathecal
injections and subjects experiencing endpoint events were com-
pared with the χ2 test or Fisher exact test for categorical variables,
and the t-test or non-parametric test for continuous variables.
Survival graphs were drawn using the Kaplan-Meier method and
compared by the log-rank test using censored data. CNS relapse
graphs were determined using the competing risk method, in
which death in remission and non-CNS relapse were competing
events, and compared with the Gray non-parametric test. P values
are two-sided. 
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Table 1. Demographic and clinical characteristics of the study patients.
CNS prophylaxis trial
All patients ITT ITD
(n=145) (n=74) (n=71) P value
Age (years), median (range) 42.0 (18.2-65.9) 42.6 (18.2-65.9) 39.7 (19.0-65.4) 0.28
<35, n. (%) 51 (35.2) 20 (27.4) 31 (43.7) 0.08
35-55 69 (47.6) 38 (51.4) 31 (43.7)
>55 25 (17.2) 16 (21.6) 9 (12.7)
Gender (M), n. (%) 88 (60.7) 47 (63.5) 41 (57.8) 0.48
Hemoglobin (g/L) 9.9 (3.4-16.8) 9.9 (3.7-15.5) 10.2 (3.4-16.8) 0.81
White blood cell count (x109/L) 15.4 (0.6-1021) 15.6 (0.6-1021) 15.4 (1.5-350) 0.93
Blast count (x109/L) 55 (0-100) 50 (0-100) 60 (0-98) 0.56
Platelets (x109/L) 58 (3-450) 63 (6-450) 53 (3-372) 0.60
LDH (U/dL), median (range) 1016 (151-17704) 1052 (176-17704) 1003 (151-5597) 1.00
Hepatomegaly, n. (%) 26 (17.9) 16 (21.6) 10 (14.1) 0.24
Splenomegaly, n. (%) 47 (32.4) 27 (36.5) 20 (28.2) 0.28
Lymphadenopathy, n. (%) 26 (17.9) 14 (18.9) 12 (16.9) 0.75
Mediastinal mass, n. (%) 15 (10.3) 8 (10.8) 7 (9.9) 0.85
CNS involvement, n. (%) 2 (1.4) 0 2 (2.8) 0.24
Immunophenotype, n. (%) 0.90
pro-B 21 (14.6) 9 (12.2) 11 (17.1)
common-B 68 (46.9) 35 (47.3) 33 (46.5)
pre-B 20 (13.9) 11 (14.9) 9 (12.9)
B-undefined 1 (0.7) 1 (1.4) 0
pro-T 5 (3.5) 2 (2.7) 3 (4.3)
pre-T 10 (6.9) 5 (6.8) 5 (7.1)
cortical-T 16 (11.1) 8 (10.8) 8 (11.4)
mature-T 4 (2.8) 3 (4.1) 1 (1.4)
Cytogenetics/genetics, n. (%)
Adverse
t(9;22)/BCR-ABL 32 (22.1) 17 (23.0) 15 (21.1) 0.79
t(4;11/MLL-AF4) 10 (6.9) 5 (6.8) 5 (7.1) 1.00
other 16 (11.0) 10 (13.5) 6 (8.5) 0.33
Non-adverse
t(1;19)/E2A-PBX1 1 (0.7) 0 1 (1.4) 0.49
hyperdiploid 2 (1.4) 1 (1.4) 1 (1.4) 1.00
other 13 (9.0) 6 (8.1) 7 (9.9) 0.71
normal 55 (37.9) 25 (33.8) 30 (42.2) 0.29
not known 16 (11.0) 10 (13.5) 6 (8.5) 0.33
Risk stratification, n. (%)
B-precursor
standard-risk 40 (27.6) 20 (27.0) 20 (28.2) 0.88
high-risk 11 (7.6) 6 (8.1) 5 (7.0) 0.81
very high risk 59 (40.7) 30 (40.5) 29 (40.9) 0.97
T-precursor
standard-risk 8 (5.5) 4 (5.4) 4 (5.6) 1.00
very high risk 27 (18.6) 14 (18.9) 13 (18.3) 0.93
Results
Study patients
The study was conducted between January, 2008 and
August, 2012, when it was closed, after the randomization
of 145 out of 150 planned patients, due to a safety issue
raised by the European Medicine Agency, concerning a
risk of microbial contamination of DepoCyte® vials
(EMA/555991/2012). Out of 151 eligible patients, six
refused randomization and therefore received standard
ITT prophylaxis (Figure 2). Table 1 shows the diagnostic
characteristics of the patients, comparing those in the
standard ITT arm (n=74) and the experimental ITD arm
(n=71). The median age of the patients was 42 years
(range, 18.2-65.9 years) and no difference between the
patients in the two study arms was detected. Overall the
complete remission rate was 89.3% (n=183) with identical
rates across CNS trial and non-trial subsets, leaving 66 and
64 evaluable patients with complete remission in the two
trial arms.
Feasibility and toxicity of central nervous 
system prophylaxis
After exclusion of early study losses caused by resist-
ance, relapse, HSCT or death in remission, the feasibility
of intrathecal prophylaxis did not differ significantly
between the ITT and ITD arms, yielding an intrathecal
prophylaxis realization ratio of 0.84 and 0.82, respectively
(Figure 2). Discontinuation for reasons other than resist-
ance/relapse, death and HSCT included persistent hema-
totoxicity (n=3), other toxicity (n=6), technical failure
(n=2) and patient’s refusal (n=1) in the ITT arm; and per-
sistent hematotoxicity (n=1), other toxicity (n=5) and
patient’s wish for concurrent seminoma therapy (n=1) in
the ITD arm.  However, four patients randomized to ITD
were forced to discontinue intrathecal prophylaxis on
account of serious neurotoxicity whereas none had to do
so in the ITT arm, a difference which was close to being
statistically significant (P=0.06). The overall assessment of
neurotoxicity by ITD was a major study endpoint.
Altogether ITD proved more toxic than ITT, across all tox-
icity levels (Figures 2 and 3A). In the ITD arm 17 patients
(24%) suffered from CTC grade 3-4 neurotoxicity com-
pared with only two (3%) in the ITT arm (P=0.0002), and
significantly more patients developed multiple and/or
recurrent adverse events (Table 2A). The median number
of episodes of neurotoxicity of any grade per patient was
one (range, 0-8), compared to zero  (range, 0-15) in the ITT
arm (P=0.001). The most unfavourable subset comprised
ten patients reporting more than three episodes of neuro-
toxicity (14% of randomized patients), for a total of 19
grade 3-4 symptoms, in comparison with only two similar
patients in the ITT arm (2.7% of randomized patients),
none of whom had grade 3-4 neurotoxicity (P=0.02).
Types of neurological adverse events are detailed in the
Online Supplement. The prevailing symptoms were pain
and headache caused by meningeal/radicular irritation.
Other grade 3-4 toxicities in the ITD arm consisted of
altered consciousness (n=4 distinct episodes), syncope
(n=2), seizure (n=2), loss of vision (n=1), cranial neuropa-
thy (n=1), motor neuropathy (n=3) and dizziness (n=1).
Although none of these complications proved irreversible
or fatal, they caused temporary disability, hospital admis-
sion, treatment delay and/or permanent withdrawal of
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Table 2. Comparative incidence of isolated or multiple and recurrent neurotoxic adverse events due to intrathecal CNS prophylaxis in (A) the ITT
and ITD study arms, and in (B) the ITD versus dexamethasone/ITD subgroups of the ITD study arm. GI-IV denotes increasing grades of neurotoxicity
according to the CTC evaluation scale.
A ITT (n=74) ITD (n=71 ) P
Study arms G1 G2 G3 G4 Patients G1 G2 G3 G4 Patients
Neurotoxicity episodes (n.),
1 5 6 1 0 12 4 6 2 1 13 0.74
2 0 4 0 0 2 5 6 8 1 10 0.02
3 0 7 1 1 3 7 3 2 0 4 0.72
>3 5 14 0 0 2 5 29 14 5 10 0.02
N. of patients (%),
total 19 (25.6) 37 (52.1) 0.001
with >1 episode 7 (9.4) 24 (33.8) 0.0004
with 1 GIII-IV episode 1 (1.4) 3 (4.2) 0.36
with >1 GIII-IV episode 1 (1.4) 14 (19.7) 0.0003
B ITD (n=35) Dexamethasone/ITD (n=36) P*
ITD subgroups G1 G2 G3 G4 Patients G1 G2 G3 G4 Patients
Neurotoxicity episodes (n.),
1 3 3 0 0 6 1 3 2 1 7 0.80, 0.67
2 3 4 4 1 6 2 6 4 0 4 0.50, 0.09
3 2 1 0 0 1 5 2 2 0 3 0.61, 0.39
>3 3 22 13 5 8 2 7 1 0 2 0.04, 0.60
N. of patients (%),
total 21 (60.0) 16 (44.4) 0.19, 0.05
with >1 episode 15 (42.9) 9 (25.0) 0.11, 0.03
with 1 GIII-IV episode 0 3 (8.3) 0.24, 0.10
with >1 GIII-IV episode 9 (25.7) 5 (13.9) 0.21, 0.01
*comparing dexamethasone/ITD vs. ITD (first value) or ITT (second value).
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Figure 2. CONSORT diagram showing study flow, pri-
mary endpoint results (feasibility and toxicity of ITD
compared to ITT) and clinical outcomes [rates of com-
plete remission (CRI), early study drop-out, relapse and
survival]. 
Figure 3. Comparative analysis of neurotoxicity according to (A) CTC
grading and (B) treatment cycle and ALL immunophenotype in the
ITD arm and the ITT arm. 
A
B
P= 0.85
P= 0.20
P= 0.30
P= 0.54
P= 0.06
P= 0.26
P= 0.62
P= 1.00
P= 0.50
P= 0.42
P= 1.00
P= 0.68
P= 0.21
P= 0.38
P= 0.002
intrathecal prophylaxis in some cases (n=4). 
A secondary toxicity analysis concerned the different
ITD schedule adopted in B- and T-ALL, and the adjunct of
intrathecal dexamethasone decided at the interim analy-
sis. Grade 3-4 neurotoxicity by ITD was more common in
T-ALL [6/17 (35%) versus 11/54 (20%) with B-ALL] at
treatment cycles 1-2 and 8 (Figure 3B), when ITD was
administered every 2 weeks three and two consecutive
times, respectively (Figure 1). The addition of intrathecal
dexamethasone 4 mg to each ITD in the second part of the
trial led to a slight reduction of overall neurotoxicity, with
a more definite effect on the incidence of multiple adverse
events, since the proportion of patients with more than
three toxicities decreased from 22.8% (n=8/35) to 5.5%
(n=2/36, P=0.04), and there was a decrease in grade 3-4
toxicities from 18 episodes in eight patients (2.25 per
patient) to one episode in two patients (0.5 per patient)
(Table 2B). The improved toxicity profile of the intrathecal
dexamethasone/ITD combination was further underlined
by the loss or marked reduction of the statistical signifi-
cance concerning the incidence of neurotoxic complica-
tions in comparison with the ITT arm.    
Efficacy of central nervous system prophylaxis and gen-
eral outcome measures
In the ITD arm there were two delayed isolated CNS
relapses (1 Ph– and 1 Ph+ B-ALL) at 603 and 704 days, com-
pared to four total CNS relapses (1 T-ALL, 1 Ph– and 2 Ph+
B-ALL) at days 75, 281, 348 and 572 in the ITT arm (Figure
4A). All CNS relapses but one (in the ITT arm) were
observed in patients who did not undergo HSCT. The sin-
gle relapsed Ph+ patient in the ITD arm was older than 55
years and was not given any systemic high-dose
chemotherapy because of a poor performance status.
Thus, provided at least one high-dose course was given
concomitantly, the incidence of any CNS recurrence was
1.5% in the ITD arm (0% in T-ALL), and 6% in the ITT
arm (5.6% in T-ALL). Median and 4-year overall survival
and disease-free survival estimates were similar in the ITT
and ITD arms (Figure 4B,C).
Discussion 
This trial was undertaken to evaluate the overall
risk/benefit profile of ITD in the prophylaxis of meningeal
relapse in adult ALL, primarily to assess and monitor the
feasibility and safety of intrathecal therapy. ITD is a slow-
release liposome-encapsulated cytarabine formulation,
considered here because of its marked activity in neoplas-
tic meningitis caused by solid tumors, lymphoma and
ALL.16,23,24 CNS relapse confers a very bad outlook and is
still observed in some patients with ALL. ITD could help
optimize the design of modern radiation-free prophylactic
regimens and improve the compliance to intrathecal ther-
apy of patients at high risk of complications, such as the
elderly and those with Ph+ ALL,25-27 limiting the total num-
ber of lumbar punctures to six or fewer. In the German
elderly Ph– ALL trial,25 the use of ITD instead of intrathecal
methotrexate reduced induction mortality compared to
that in a historical cohort of patients. Another clinical
advantage of ITD-based, radiation-free CNS prophylaxis
would be the lack of the chemotherapy delays typically
associated with the application of cranial irradiation. It
was, therefore, disappointing that five of 31 patients in the
first ITD trial from MDACC developed unacceptable neu-
rotoxicity,18 as reported in 10% or more of the patients
enrolled in other ITD studies.28,29
In our randomized phase II trial with systemic HD-
M/A, the dose of methotrexate was 1.5, 2.5 or 5 g/m2
(depending on the patients’ age and disease subset) and
that of cytarabine was 2 g/m2, while intervals between
any prior or subsequent ITD and/or HD-M/A were set at
21 days and not 10-14 days (MDACC study). This gave us
the opportunity to compare directly the cumulative CNS
toxicity of these drugs in conjunction with either ITT or
ITD given at the stated intervals. The only exception to
this design concerned patients with T-ALL, who received
additional ITD at cycles 1 and 8, shortening this interval to
14 days for three and two consecutive ITD administra-
tions, respectively. 
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Figure 4. CNS relapse incidence and outcome estimates with 95%
confidence intervals (CI) by randomization arm. (A) Three-year CNS
relapse incidence: ITT (n=66), four CNS relapses (6.1%, 95% CI 2-
14%), two isolated (3%, 95% CI 0.6-9%) and two combined (3.1%,
95% CI 0.6-9%); ITD (n=64), two isolated CNS relapses (3.1%, 95%
CI 0.8-14%) (P=0.43). (B) Overall survival: ITT (n=74), median dura-
tion 4.5 years, 62% at 3 years (95% CI 49-74%)  and 58% at 4 years
(95% CI 44-72%); ITD (n=71), median duration 4.0 years, 53% at 3
and 4 years (95% CI 40-66%) (P=0.44). (C) Disease-free survival: ITT
(n=66), median duration not reached, 54% at 3 and 4 years (95% CI
40-67%); ITD (n=64), median duration 3.9 years, 53% at 3 years
(95% CI 39-66%) and 48% at 4 years (95% CI 34-63%) (P=0.54). 
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As to study design, the expected CNS progression rate
in the standard ITT arm was 5% or less, to be compared
with a similar or even lower figure in the ITD arm. With
this preliminary consideration, a formal sample size calcu-
lation according to classical statistical tenets would give
rise to a disproportionately high number of patients to be
recruited for an efficacy study, not met by the planned
number of study subjects (n=150). However, because of
the inconsistency of comparative neurotoxicity data in the
CNS prophylaxis of adult ALL and the need to adequately
screen ITD in combination with systemic chemotherapy,
it was nevertheless decided to privilege the collection of
standardized, methodologically sound data in the context
of a phase II randomized clinical trial.30 In this regard, it is
not easy to translate a comparison of CNS recurrence rate
and drug-related neurotoxicity into an a priori calculation
of expected adverse events, which were instead explored
and described to provide a logical basis for discussion
and/or larger studies. 
The study results indicated a significantly higher neuro-
toxicity from ITD than from ITT. Overall, 17 patients in
the ITD arm developed one or more episodes of grade 3-4
neurotoxicity (24%). Excluding the more easily manage-
able cases of high-grade, transient inflammatory/radicular
pain or headache, eight of the 17 patients including six
patients in complete remission (9.4%) suffered from seri-
ous, debilitating neurological symptoms, such as disturbed
consciousness, cranial and/or peripheral neuropathy,
seizure and loss of vision. This often led to hospital read-
mission and caused permanent discontinuation of CNS
prophylaxis in four patients. Although none of these
patients had a CNS relapse, this type and rate of clinical
complications is hardly acceptable in a prophylactic regi-
men for adult ALL, because not previously reported with
the traditional intrathecal methotrexate or ITT, as clearly
confirmed by the results in the standard arm of the trial.
However, ITD-related toxicity was eventually reversible
and no patient developed a conus syndrome or died of
these complications, which might suggest some benefit
from increasing the intervals between ITD and HD-M/A
courses and lowering the intravenous cytarabine dose
compared to that used in the MDACC study (from 3 to 2
g/m2). Because the majority of the affected patients
resumed ITD prophylaxis, albeit at an initially lower
dosage (25 mg), the ITD program resulted statistically fea-
sible in comparison with the ITT control arm.
Other study results deserve to be discussed, since neu-
rotoxicity due to ITD is rather unpredictable and has not
been associated with any specific disease subset or drug
scheduling. In this trial the incidence of grade 3-4 neuro-
toxicity was both higher and worse in patients with T-
ALL who received, by design, ITD every 14 days at cycles
1-2 and 8. Thus a longer than 21-day interval could  lower
the risk of neurotoxicity, as for ITD and HD-M/A courses.
With regards to intrathecal dexamethasone added to ITD
following the interim analysis, the risk of neurotoxicity
was slightly lower and that of multiple grade 3-4 toxicities
was significantly lower and closer to that observed in the
ITT arm, independently of the concurrent use of intra-
venous dexamethasone as per protocol specifications.
This could be explained by a greater dexamethasone con-
centration achieved in the cerebrospinal fluid immediately
before ITD administration, reducing the risk of  acute
meningeal reactions.  
With regards to the efficacy analysis, which remains basi-
cally undefined due to the very small number of expected
events relative to the total number of study patients, the risk
of CNS relapse was low in the ITD arm, especially in
patients with T-ALL (0%) and also in patients with Ph– B-
ALL provided at least one HD-M/A course was given con-
comitantly (1.5%). This, together with the MDACC study
results (no CNS relapses), would suggest that ITD plus HD-
M/A represents a powerful radiation-free combination for
CNS prophylaxis, perhaps with an increased efficacy in T-
ALL in relation to the higher methotrexate dose of  5 g/m2
used in our study. In contrast to the German trial in the eld-
erly,25 the complete remission rate was not improved in the
ITD arm; however, since this was already in a high range for
this cohort of patients aged 18.2-65.9 years (89% in the ITT
arm) we argue that it could not be increased significantly.
ITD 50 mg is the most effective drug for intrathecal injec-
tion or administration via an Ommaya reservoir for
meningeal ALL. Its use as a prophylactic agent was prompt-
ed by the awareness of the poor outcome of patients fol-
lowing CNS relapse. So far, 102 patients have been enrolled
and received ITD in two distinct prospective studies of pri-
mary CNS prophylaxis: 31 in the MDACC phase II trial and
71 in the NILG phase II randomized trial. Both studies con-
firmed a risk of serious CNS toxicity greater than 10%,
related to the sustained drug release in the cerebrospinal
fluid and potentiated by a temporally close exposure to sys-
temic high-dose cytarabine; the risk seems too high to rec-
ommend this drug as standard intrathecal prophylaxis with
ALL regimens combining ITD with HD-M/A courses. At
the same time, because ITD is highly active against CNS
leukemia, it would be wrong to discard this agent from the
search for an optimal radiation-free prophylactic regimen.
Especially in patients with ALL subsets at higher risk of
CNS progression, this search could entail an evaluation of
lower doses (15-25 mg), which may retain significant phar-
macological activity15 while having a safer toxicity profile,
the association with intrathecal dexamethasone, and avoid-
ance of temporally too close administration of ITD and any
prior or subsequent ITD or HD-M/A.
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